Friday: May 1, 2020
18.30 - 20.00
Saturday: May 2, 2020
07.30 - 08.00
08.00 - 08.10
08.10 - 08.15
Introduction & Meeting Objectives
08.15 - 10.15
Session I: New challenges in genomics
Part 1: Current challenges in clinical genomics
- How to identify and counsel a patient with a suspected germline abn in practice
- CHIP/ACUS in the general population: what we know and what we do with it
- Genetics and epigenetics IDH mutations/biology
- How to use genomics for prognosis assessment in AML
- Should pre-transplant MRD be suppressed or not?
Part 2: How can we target LSCs?
- Latest concepts in biology of leukemic stem cells
- Novel Ab approaches for targeting leukemic stem cells
- Fitness of leukemic stem cells
10.15 - 10.30
10.30 - 12.15
Session 2: What is standard of care in AML in 2020?
- Fit AML over 60yo: 7+3 or not?
- Secondary AML
- Maintenance therapy with oral AZA-QUAZAR
- Which patients should have allo transplant in 2020?
- Unfit AML with IDH mutation – Venetoclax or IDHi?
- Relapsed FLT3 mutant AML
- Post-SCT maintenance in AML
- DHODH inhibition in AML
- MDM2 inhibition in R/R AML
12.15 - 13.15
Session 3: New clinical trial designs to accelerate drug development
- Novel therapeutic platforms
- Translating research into practice
- EFS or OS for frontline clinical trials in AML?
- Clinical trial designs centered on MRD as an eligibility criterion or study endpoint
- Transplantation trial networks
13.15 - 14.15
14.15 - 16.00
Session 4: Novel treatment strategies in ALL
- Progress and lessons learned from pediatric ALL
- Which patients with ALL should have a transplant in first CR?
- How to improve MRD detection: ddPCR, NGS
- Progress in treatment of AYA
- Do we still need chemotherapy in Ph+ ALL?
- Innovation in the treatment of T-ALL
16.00 - 17.30
Session 5: Can we truly integrate MRD measurement into AML clinical practice?
- CHIP mutations detectable at the time of response
- Single cell sequencing and clinical applicability in detection and therapy of AML
- How can we apply MRD into clinical practice?
Sunday: May 3, 2020
08.00 - 08.15
08.15 - 11.15
Session 6: Novel targets, combinations and treatments in AML
Part 1: What is the next AML blockbuster?
- New FLT3 inhibitors and combinations
- Antibody-drug conjugates
- Anti-CD70: cusatuzumab
Part 2: What do we know about drug resistance?
- Resistance to IDHi
- Targeting resistance to Venetoclax based therapies
- Resistance to FLT3 inhibitors
- Epigenetic therapies
11.15 - 13.00
Session 7: Immunotherapy in ALL
- Blinatumomab from relapse to front-line therapy
- Inotuzumab from relapse to front-line therapy
- Nk/other cellular therapies
- Allogenic CAR-T/UCART19
- CAR-T in ALL
13.00 - 13.45
13.45 - 15.45
Session 8: Immunotherapeutics in AML
- Biomarkers of sensitivity and mechanisms of resistance to immune checkpoint therapies in AML
- Bispecifics/BiTes in AML
- T-cells in AML: function, distribution and therapeutic potential
Part 2: CAR-T/cellular
- Which CAR-T cell strategy in AML has the most promise/potential vs pitfalls
- Cell therapy development for myeloid diseases: balancing efficacy and toxicity
- AML for CAR-T – targeting CD123
- CAR NKs and other constructs
Final Meeting Summary & Conclusions
Sheraton Tampa Riverwalk Hotel
200 North Ashley Drive, Tampa,
Florida, 33602 USA